Ferrous Succinate is a pharmaceutical salt formed by ionic pairing of the active pharmacophore with a carefully selected counter-ion to optimise aqueous solubility, crystallinity, dissolution rate, and solid-state stability relative to the parent free form. Salt selection is a pivotal pharmaceutical development decision influencing polymorphic landscape, hygroscopicity, powder flow, compressibility, and bioavailability. Characterisation of Ferrous Succinate by XRPD, DSC, TGA, and dynamic vapour sorption is essential to define the approved solid-state form and ensure consistent quality across manufacturing batches.
ICH Q3A qualification thresholds for impurities in new drug substances require toxicological qualification of individual impurities of Ferrous Succinate exceeding the reporting threshold (0.05% or 1 mg TDI, whichever is lower), identification threshold (0.10% or 2 mg TDI), and qualification threshold (0.15% or 2 mg TDI).
